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A systematic review and meta-analysis of the
treatments of varicose veins
M. Hassan Murad, MD, MPH,a,b,c Fernando Coto-Yglesias, MD,a,d Magaly Zumaeta-Garcia, MD,a
Mohamed B. Elamin, MBBS,a Murali K. Duggirala, MD,a,c Patricia J. Erwin, MLS,a
Victor M. Montori, MD, MSc,a,c,e and Peter Gloviczki, MD,f Rochester, Minn; and San José, Costa Rica
Objectives: Several treatment options exist for varicose veins. In this review we summarize the available evidence derived
from comparative studies about the relative safety and efficacy of these treatments.
Methods: We searched MEDLINE, Embase, Current Contents, Cochrane Central Register of Controlled Trials
(CENTRAL) expert files, and the reference section of included articles. Eligible studies compared two or more of the
available treatments (surgery, liquid or foam sclerotherapy, laser, radiofrequency ablations, or conservative therapy
with compression stockings). Two independent reviewers determined study eligibility and extracted descriptive,
methodologic, and outcome data. We used random-effects meta-analysis to pool relative risks (RR) and 95%
confidence intervals (CI) across studies.
Results:We found 39 eligible studies (30were randomized trials) enrolling 8285 participants. Surgery was associated with
a nonsignificant reduction in the risk of varicose vein recurrence compared with liquid sclerotherapy (RR, 0.56; 95% CI,
0.29-1.06) and all endoluminal interventions (RR, 0.63; 95% CI, 0.37-1.07). Studies of laser and radiofrequency
ablation and foam sclerotherapy demonstrated short-term effectiveness and safety. The quality of evidence presented in
this review was limited by imprecision (small number of events), short-term follow-up, and indirectness (use of surrogate
outcomes).
Conclusion: Low-quality evidence supports long-term safety and efficacy of surgery for the treatment of varicose veins.
Short-term studies support the efficacy of less invasive treatments, which are associated with less periprocedural disability
and pain. (J Vasc Surg 2011;53:49S-65S.)
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vApproximately one-third of men and women aged 18
to 64 years have varicose veins.1 The high prevalence leads
to significant health care expenditure on treatments of
varicose veins.2 Surgical treatment of varicose veins in-
cludes high ligation and saphenous vein stripping, with or
without phlebectomy; until the past few years, this proce-
dure had been used most commonly by surgeons world-
wide.3-5 However, several other less invasive treatment
modalities that are claimed to be as effective as surgery are
currently available, including radiofrequency or laser abla-
tion of the great (GSV) or small saphenous veins (SSV), or
both, combined with or without phlebectomy, liquid scle-
rotherapy,2,6 and foam sclerotherapy.7-9 Numerous ran-
domized controlled trials (RCTs) and observational studies
have compared the efficacy of these procedures, but to our
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The Society for Vascular Surgery (SVS) partnered with
he American Venous Forum (AVF) to develop clinical
ractice guidelines to improve the care of patients with
enous disease. To assist in venous guideline development,
he SVS and the AVF commissioned us to conduct this
ystematic review and meta-analysis to summarize the best-
vailable evidence about the benefits and harms of the
ifferent treatments of varicose veins.
ETHODS
The report of this protocol-driven systematic review
as approved by the VenousDisease Committee of the SVS
nd the AVF and adheres to the Quality of Reporting of
eta-analyses (QUOROM) standards for reporting sys-
ematic reviews of RCTs and reporting Meta-analyses of
bservational Studies in Epidemiology (MOOSE).10,11
he quality if evidence was rated using the Grading of
ecommendations Assessment, Development, and Evalu-
tion (GRADE) framework.12
Eligibility criteria. Eligible studies were RCTs and
ohort studies that enrolled participants with primary vari-
ose veins who were treated with surgery, sclerotherapy,
oam sclerotherapy, percutaneous endovenous thermal in-
erventions (ablation with radiofrequency or laser), or con-
ervative management with compression stockings. We in-
luded studies that measured any of the outcomes of
aricose veins recurrence, patient satisfaction, esthetics,
ime to return to work, pain, and procedurally related
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May Supplement 201150S Murad et alcomplications, including local wound complications, such
as infection and hematoma, and systemic complications,
including deep vein thrombosis (DVT), pulmonary embo-
lism (PE), air embolism, and pulmonary fibrosis. Studies
were included regardless of their language, sample size,
surgical technique, or duration of patient follow-up. We
excluded single-cohort studies (ie, studies in which all
patients received the same treatment without concurrent
comparison groups).
Study identification and data collection. An expert
reference librarian (P.J.E.) designed and conducted the
electronic search strategy with input from study investiga-
tors with expertise in conducting systematic reviews. To
identify eligible studies, we searched electronic databases
(MEDLINE, Embase, Cochrane CENTRAL, Web of Sci-
ence, and Scopus) through February 2008 and monitored
the literature for new publications thereafter. We also
sought references from experts, bibliographies of included
trials, and the Institute for Scientific Information Science
Citation Index for publications that cited included studies.
A combination of subject headings and text words were
used as needed to define varicosities and the various proce-
dures. Results were limited to comparative studies. The
detailed search strategy is available from the authors upon
request.
References were uploaded in a Web-based software
Fig. Flow chart shows the processpackage developed for systematic review data management oSRS, TrialStat Corp, Ottawa, Ontario, Canada). Paired
eviewers working independently screened all titles and
bstracts for eligibility. References that were deemed po-
entially relevant were retrieved in full text and uploaded for
ull text evaluation against eligibility criteria. The chance-
djusted inter-reviewer agreement ( statistic) for study
ligibility was 0.79 (95% confidence interval [CI], 0.66-
.93). Disagreements were resolved by consensus (the two
eviewers discussed the study and reached a consensus), and
hen disagreement continued, by arbitration (a third re-
iewer adjudicated the study). Teams of two reviewers
orking independently and using a standardized form ex-
racted data in duplicate from all eligible studies, including
tudy description, methodologic quality, and outcome
ata.
tatistical analysis
Meta-analyses. When appropriate, we pooled relative
isks (RR) for dichotomous outcomes from each trial using
he DerSimonian-Laird random effects model and esti-
ated the 95% CI for each outcome to reflect the uncer-
ainty of point estimates of effect.13 A RR of 1.0 indicates
o difference between the two interventions in association
ith a particular outcome. A RR 1.0 indicates that com-
ared with the control intervention, the procedure in-
reased the risk of outcome occurrence. For continuous
dy selection for the meta-analysis.utcomes, we planned to estimate the weighted effect size
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Volume 53, Number 16S Murad et al 51Sand the 95% CI, and for outcomes assessed with multiple
scales, we planned to estimate the standarized mean differ-
ence. We used the I2 statistic, which estimates the percent-
age of total variation across studies that is due to heteroge-
neity rather than chance (ie, the percentage of variability in
treatment effects across trials that is not due to chance or
random error, but rather due to real differences in study
patients, design or interventions).14 The I2 values of25%,
50%, and 75% represent low, moderate, and high incon-
sistency, respectively. Statistical analysis was conducted us-
ing StatsDirect 2.5.4 software (StatsDirect Ltd, Cheshire,
United Kingdom).
Subgroup and sensitivity analyses. Our a priori hy-
potheses to explore subgroup interactions and explain in-
consistencies in the direction and magnitude of effect
among studies included variation in bias protection mea-
sures and patient characteristics such as sex. We also
planned to stratify results according to severity of chronic
venous disease using the CEAP classification, when re-
ported (published in 1994 and revised in 2004).15 We
planned to test the hypotheses of a subgroup effect using a
test of interaction16 and to conduct meta-regression to
assess the correlation between the effect size and the length
of study follow-up. Sensitivity analysis to exclude short-
term studies that were unlikely to evaluate outcome of
interest was also conducted.
RESULTS
Study identification. The Fig depicts our search and
selection procedures. The initial search yielded 1185 refer-
ences, from which we found 44 eligible articles represent-
ing 39 unique studies. Table I summarizes the characteris-
tics and quality indicators of the included studies. These
studies compared different permutations of the available
treatment modalities for varicose veins and enrolled 8285
participants, with a mean sample size of 225 and mean
duration of follow-up of 31 months (range, 3 months-10
years). The study patients were a mean age of 49, and 70%
were women.
Methodologic quality. We considered an ideal study
to have randomization with concealed allocation, blinding
of outcome assessors (realizing that blinding of patients
and surgeon is not feasible) and follow-up duration that
exceeded 3 years, with minimal loss to follow-up.
Of the included studies, 9 were observational,17-25 1
was quasi-randomized,26 and 30 were randomized.26-55
Allocation concealment was conducted in five of the RCTs
(three by sealed envelope and two by central randomiza-
tion),32,33,52,55,56 only two RCTs used blind outcome
assessors,18,40 and one blinded patients.37
In the observational studies, it was difficult to ascer-
tain whether study arms were comparable at baseline.
Study arms were often imbalanced in size, suggesting
surgical expertise or preference for a particular proce-
dure; in some studies, sclerotherapy was restricted to
patients without saphenofemoral or saphenopopliteal
incompetence.20 Analysis usually was adjusted for age
and sex. Blinded outcome assessment was rarely con- fiucted.18 Loss to follow-up was often not reported, or
as reported as high (median, 9%; range, 0%-50%), and
as significantly different between study arms on several
ccasions.32,34,44,55 Seven studies17,18,32,34,43,48,55 re-
orted for-profit funding sources, whereas most did not
eport a funding source.
Outcome ascertainment was judged to be adequate in all
tudies (clinical outcomeswere ascertained by clinical encoun-
er or record review, whereas patient satisfaction, pain, or
uality of life were assessed by standarized questionnaires).
eviewers had adequate chance-adjusted agreement in judg-
ng study quality (k  .83-.92). Table I summarizes the
ethodologic quality of the included studies.
Outcomes. The results of different comparisons are
resented in the following format: description of included
tudies, reported outcomes, meta-analysis if applicable or
easible, and the overall quality of evidence.
clerotherapy studies
Liquid sclerotherapy vs various surgical techni-
ues. RCTs and observational studies published in the
960s and 1970s showed that sclerotherapy was as effective
s surgery, particularly in patients without incompetent
erforating veins.56 In addition, patients in these studies
referred sclerotherapy,33 which gave better initial results26
nd was less likely to require additional treatment.31 How-
ver, studies with longer follow-up periods suggested that
he initial benefits of sclerotherapy declined over time. For
nstance, Hobbs et al41 found that surgery seemed more
ffective than sclerotherapy after 6 years and when the
ondition involved the saphenous system and there was
roximal incompetence. Similarly, in another RCT, 5-year
ailure rates were 10% in surgical patients vs 74% in the
ompression sclerotherapy group.38
Even when liquid sclerotherapy (hydroxypoly-
thoxydodecane injected in the main stem of GSV) was
oupled with high ligation of the saphenofemoral junc-
ion under local anesthesia, it remained at 5 years inferior
o stripping and ligation of GSV and incompetent perfo-
ators in patient satisfaction and cure rate.46 Heated
olidocanol administered via a catheter advanced in the
SV from the knee level to the saphenofemoral junction
SFJ) was similarly inferior to surgery (ligation of SFJ
nd incompetent veins detected by color duplex imag-
ng) after 10 years of follow-up.30
When one RCT with 10-year follow-up compared six
reatment options—liquid sclerotherapy, high-dose liquid
clerotherapy, multiple ligations, stab avulsion, foam-
clerotherapy, and high ligation, followed by sclerotherapy—
ll treatments appeared equally effective in recurrence.28
mbulatory phlebectomy was superior to compression
clerotherapy in one RCT, with lower recurrence rates at 1
nd 2 years.36 Likewise, the recurrence-free rate at 4 years
81.7%) in patients who received stripping was superior to
he rates achieved by saphenofemoral ligation (64.5%) or
iquid sclerotherapy with 1% to 2% polidocanol
51.3%).22 Sclerotherapy was suggested as a more bene-
cial treatment than surgery when the SSV is involved
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First author, year
Population
Intervention 1
No. patient (limb)
Intervention 2
No. patient (limb)
Postprocedure
surveillance FU
(Anatomy, age, sex,
CEAP)
Surgery vs sclerotherapy
Hobbs41,56 (1968, 1974) Lower extremity
VV;
nonpregnant,
healthy
population; age
and sex NR
Sclerotherapy (injection-
compression):
211 (542)
SF ligation, GSV/
SSV stripping,
multiple
extrafascial
ligations,
removal of VV
clumps and
subfascial
ligation of
perforating
veins: 170 (226)
Clinical assessment
and photograph
1 year
Chant33 (1972) Lower extremity
VV; age and sex
NR
Sclerotherapy (Fagan:
injection-compression):
115
Surgery: 100 Physical examination,
interview,
questionnaire
3 years
Doran26 (1975) Lower extremity
VV; age and sex
NR
Sclerotherapy (Fagan:
injection-compression;
Ethamolin):
182 (280)
Surgery: 149 (222) Physical examination 2 years
Beresford31 (1978) Lower extremity
VV; age 15-64;
sex NR
Sclerotherapy (Fagan:
injection-compression;
Ethamolin): 125
Surgery: 124 Questionnaire,
interview, physical
examination
5 years
Trempe23 (1991) VV of SSV; age
43 (22-69); 93%
women
Sclerotherapy (multiple
agents): 138 (148)
Surgery: 112 (290) Medical record
review
7 years
Einarsson38 (1993) Symptomatic
primary VV; age
42 (21-45); 69%
women
Sclerotherapy: 84 (85) Surgery: 80 (82) Clinical tests and foot
volumetry
5 years
Neglén46 (1993) Primary VV  GSV
insufficiency; age
47; 64% women
Sclerotherapy: (78) Surgery: (74) Clinical interview,
examination, foot-
volumetry
5 years
Ishikawa20 (1998) Primary VV; age
56 (21-81); 82%
women
Sclerotherapy: (81) High saphenous
ligation: (3)
Clinical assessment,
Doppler US
26 months
Belcaro30 (2000) VV/pure superficial
venous
incompetence;
age 53, 47%
women
Endovascular
sclerotherapy
(polidocanol): 39
Flush ligation of
SPJ, collaterals
and all
incompetent
veins: 42
Color DUS,
ambulatory venous
pressure
10 years
Belcaro28 (2003) Primary VV; age
45, 69% women
Sclerotherapy (various
techniques): 434
Stab avulsion or
multiple ligation:
299
DUS 10 years
De Roos36 (2003) Chronic venous
disease; age
42 (25-65); 98%
women; C2 Ep
A5 Pr
Sclerotherapy
(polidocanol):
48 (49)
Ambulatory
phlebectomy:
48 (49)
Doppler US,
continuous-wave
US Doppler,
digital photo-
plethysmography
2 years
Miyazaki22 (2005) Primary VV due to
GSV
insufficiency; age
58; 76% women;
C2-3 (76%), C4-6
(24%)
Sclerotherapy
(polidocanol): (38)
Stripping: (244) Clinical assessment 4 years
Sclerotherapy vs
conservative
management
Abramowitz27 (1973) Pregnant women
with lower leg
Conservative
management with
Compressive
sclerotherapy: 45
Physical examination 6-24 monthsVV, age NR stockings: 56
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Design Funding Lost to FU Outcome assessors blinded? Allocation concealed?
Control for risk factors in
selection or analysisa
R NFP NR No/NR Sealed envelope NA
R NFP 7% No/NR Sealed envelope NA
Ra NR 36%; 29% No/NR No/NR NA
R NR 8.7%; 6.1% No/NR No/NR NA
Non-R NR NR No/NR NA No/NR
R NR 22%; 24% No/NR No/NR NA
R NR 23% No/NR No/NR NA
Non-R-R NR NR No/NR NA Groups imbalanced (size and
prognosis)b
R NR 21% No/NR No/NR NA
R NFP 16% No/NR No/NR NA
R NR 2.49% No/NR No/NR NA
Non-R-P NR NR No/NR NA Analysis adjusted for age and
sex
R NFP 2%; 50% No/NR No/NR NA
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First author, year
Population
Intervention 1
No. patient (limb)
Intervention 2
No. patient (limb)
Postprocedure
surveillance FU
(Anatomy, age, sex,
CEAP)
Surgery vs conservative
management
Stacey50 (1988) Chronic
insufficiency with
healed venous
ulcers; age
61 (38-80); 43%
women
Ligation  below knee
graduated
compression elastic
stocking: (20)
Below-knee
graduated
compression
elastic stocking:
(21)
Ascending
phlebography,
plethysmography,
foot-volumetry
1 year
Belcaro29 (1992) Superficial venous
incompetence;
age 39, 67%
women
Selective saphenous vein
repair with plication
(SSVR): 22
Conservative
management
with stockings:
22
Color DUS, high-
resolution DUS,
ambulatory venous
pressure and
normal maximum
venous outflow (by
plethysmography)
5 years
Michaels44 (2006) Uncomplicated
primary VV lower
extremities; age
45, 69% women
Flush ligation of reflux
 GSV stripping: 124
Conservative
management:
122
Postal questionnaires
interview and
examination
2 years
Van Gent52 (2006) Active venous leg
ulcers; age 66,
61% women
Subfacial endoscopic
perforating vein
surgery 
compression therapy:
97
Compression
therapy: 103
Examination; DUS 2 years
Gohel39 (2007) and
Barwell67 (2004)
Open or recently
healed leg ulcers
and superficial
venous reflux;
age 73, 58%
women
Saphenous surgery 
compression: 242
Compression
therapy: 258
Examination and
QOL
questionnaires
4 years
Laser vs sclerotherapy
Coles18 (2002) Untreated VV &
lower extremity
reflux, small
diameter (0.25
and 3 mm) leg
veins; age
48 (28-68); all
women
Long pulsed ND:YAG
laser: 20
Sclerotherapy
(Sotradecol): 20
Clinical examination,
photography
3 months
Surgery vs radio
frequency
Chandler17 (2000) Primary venous
insufficiency with
GSV reflux; age
47; 77% women;
mean CEAP C 
2.3 for ligation;
2.6 no ligation
group
GSV obliteration with
Closure System:
(120)
SFJ ligation: (60) Clinical examination
and DUS
1 year
Colli19 (2005) Osteal and truncal
GSV
insufficiency; C1
(13%), C2 (40%),
C3 (33%), C4
(14%)
Radiofrequency/closure
procedure
(crossotomy 5/15;
crossectomy 1/15;
ligation 8/15): 15
Short striping
preceded by
crossectomy;
phlebectomy in
11/15: 15
6 months
Lurie43,58 (2003, 2005) Symptomatic VV
and GSV
incompetence;
age 48; 73%
women; C2
(78%-82%), C3
(9%-11%), C4
GSV obliteration with
temperature-
controlled
radiofrequency
without adjunctive
high ligation (closure
procedure): (43) 44
Stripping with high
ligation: 36 (36)
Clinical, DUS, and
QOL
questionnaire
2 years(9-11%)
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Design Funding Lost to FU Outcome assessors blinded? Allocation concealed?
Control for risk factors in
selection or analysisa
R NR NR No/NR No/NR NA
R NR 16% No/NR No/NR NA
R NFP 35%
17%
No/NR No/NR NA
R NFP 2% No/NR Central
randomization
NA
R NFP 11% No/NR Sealed envelopes NA
NonR-P FP 0% Blinded post treatment evaluators NA No/NR
NonR-P FP 0% No/NR NA Matched for age, sex, and
CEAP class
NonR-R NR NR NR NA Matched for clinical and
anatomic CEAP class
R FP 19% No/NR No/NR NA
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First author, year
Population
Intervention 1
No. patient (limb)
Intervention 2
No. patient (limb)
Postprocedure
surveillance FU
(Anatomy, age, sex,
CEAP)
Perälä47,59 (2005) Symptomatic
primary GSV
tributary VV; age
35; 93% women;
median scores in
the 2 groups:
VCSS 5/4,
VSDS 1/1, VDS
1/1
Radiofrequency
endovenous
obliteration
procedure (VNUS
closure): 15
Stripping: 13 Clinical assessment,
color DUS
3 years
Hinchliffe40 (2006) Bilateral recurrent
GSV VV
previously treated
by SF ligation;
age 54 (44-66);
75% women;
C2
Endoluminal thermal
ablation (VNUS):
16 (16)
Re-do groin
surgery and GSV
stripping:
16 (16)
DUS 1 year
Kianifard21 (2006) SFJ reflux; age
54 (28-83); 37%
women
Radiofrequency ablation
(VNUS closure):
51 (55)
Open high
saphenous tie
and stripping:
51 (55)
DUS  physical
examination
1 year
Stotter51 (2006) Primary VV; age
46; 72% women
Radiofrequency
endoluminal ablation:
20
SFJ ligation with
extended
tributary ligation
and invagination
GSV stripping:
20
Clinical assessment,
DUS, analog scale
pain scoring and
activity impairment
assessments CIVIQ
2 questionnaire
1 year
Laser vs surgery
De Medeiros35,57 (2006) Symptomatic VV
and bilateral GSV
insufficiency; age
46 (23-71); 95%
women; C2
(50%) C3 (18%),
C4 (15%), C5
(13%), C6 (4%)
Endovenous diode laser
photocoagulation:
(20)
Conventional
stripping: (20)
DUS, air
plethysmography,
questionnaire and
physical
examination
2 years
Vuylsteke54 (2006) Primary VV & GSV
insufficiency; age
40; 67% women;
C2-C4
Endovenous laser
obliteration: 80 (118)
Conventional
stripping:
84 (124)
Color DUS and
physical
examination
9 months
Rasmussen (2007)48 VV due to GSV
insufficiency; age
53 (22-79); 69%
females; 84% C2
and the rest C3-
C4
Endovenous laser
ablation: 62 (69)
High ligation and
stripping:
59 (68)
Clinical assessment,
DUS
6 months
Darwood34 (2008) Symptomatic VV
and primary SF
incompetence;
age 48 (31-59);
57% women;
most C2, the rest
are C3-C5
Endovenous laser
ablation: 65
SF ligation, GSV
stripping to the
knee and
multiple
phlebectomies:
30
DUS, clinical
examination
1 year
Foam vs surgery
Bountouroglou32 (2006) Symptomatic
primary VV due
to GSV
incompetence;
age 43 (20-72);
SFJ ligation, GSV
stripping and
phlebectomies: 28
SFJ ligation under
local anesthetic
and foam
sclerotherapy to
the GSV: 30
DUS, physical
examination,
questionnaire
3 months53% women
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Volume 53, Number 16S Murad et al 57STable I. Continued
Design Funding Lost to FU Outcome assessors blinded? Allocation concealed?
Control for risk factors in
selection or analysisa
R NR 0% No/NR No/NR NA
R NFP NR Y No/NR NA
NonR-P NFP NR No/NR NA Adjusted for age, sex
R NR 5% No/NR No/NR NA
R NR 0% No/NR No/NR NA
R NR 0% No/NR No/NR NA
R FP 27% No/NR No/NR NA
R FP 14% 7% No/NR No/NR NA
R FP 17.9% 6.7% No/NR Sealed envelope NA
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First author, year
Population
Intervention 1
No. patient (limb)
Intervention 2
No. patient (limb)
Postprocedure
surveillance FU
(Anatomy, age, sex,
CEAP)
Wright (2006)55 VV with GSV and/
or SSV
incompetence;
age 50 (18-75);
68% women; C3-
C4
Varisolve microfoam
injected under US
guidance in 5 stages;
other sclerotherapy
unspecified; Varisolve
(A)  178; Varisolve
(B)  259; other
sclerotherapy  125;
total  562
Surgery: High
ligation (91.5%);
stripping
(88.3%);
avulsion
phlebectomy
(53.2%); total 
94
Clinical assessment,
DUS
1 year
Foam vs sclerotherapy
Yamaki24 (2004) Isolated GSV
incompetence
who refused
surgical
interventions; age
54; 81% women;
C2: (75%), C3
(8%), C4 (10%),
C5 (7%)
Duplex-guided
sclerotherapy using
foamed 1% and 3%
polidocanol: 37
DUS-guided liquid
sclerotherapy: 40
DUS and air
plethysmography
1 year
Laser vs radio frequency
Morrison45 (2005) Bilateral GSV reflux Endovenous laser
ablation: 50
Radiofrequency
ablation: 50
Interview, physical
examination, DUS
1 year
Ravi25 (2006) Symptomatic VV;
age 51 (15-90);
62% women; C2
(29%), C3 (11%),
C4 (46%), C5-C6
(14%)
Endovenous laser
ablation: (1091)
Radiofrequency
ablation: (159)
Physical assessment,
DUS,
questionnaire
3 years
Laser vs conservative
management
Viarengo53 (2007) VV in lower limbs
with active ulcers;
age 59; 75%
women; C6
Endovenous laser: 27 Conservative
management
(compression
therapy): 25
Digital photograph,
US, physical
examination
1 year
Other
Jakobsen42 (1979) Untreated
saphenous VV;
81% women
Surgery (SP/SF
ligation/tributaries
avulsion): 161
Minimally invasive
surgery (ligation
under local
anesthesia) and
sclerotherapy:
157
Physical examination
 interview
3 years
Rutgers49 (1994) Isolated
incompetence of
GSV
Surgery (stripping and
local avulsions of
VV): 89
High ligation of
SFJ and
sclerotherapy: 92
DUS, physical
examination
3 years
Dwerryhouse37,61 (1999) Primary
uncomplicated
GSV VV with SFI
Flush ligation of the SFJ
with diathermy
avulsion of all visible
tributaries: 39
Stripping to the
knee and
ligation: 39
DUS, physical
examination
5 years
DUS, Duplex ultrasound; FU, follow-up; GSV, great saphenous vein; NA, not applicable; Non-R-P, nonrandomized prospective; Non-R-R, nonrandomized
retrospective; NR, not reported; QOL, quality of life; SFI, saphenofemoral incompetence; SFJ, saphenofemoral junction; SSV, short saphenous vein; US,
ultrasound; VCSS, Venous Clinical Severity Score; VSD, Venous Disability Score; VSDS, Venous Segmental Disease Score; VV, varicose veins.
aOnly applicable to nonrandomized studies.
bSurgical procedure alone performed in very little group compared with sclerotherapy group, and they restricted the treatment of sclerotherapy alone to
patients without SFI and SPI.
cPatients were blinded.
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Design Funding Lost to FU Outcome assessors blinded? Allocation concealed?
Control for risk factors in
selection or analysisa
R FP 22%
4%
No/NR Central
randomization
NA
NonR-P NR NR No/NR NA Matched for age, sex and
CEAP
R NR NR No/NR No/NR NA
NonR-R NFP NR No/NR NA No/NR
R NR 0% No/NR No/NR NA
R NR 1.90% No/NR No/NR NA
R NR 9% No/NR No/NR NA
R NR 41% No/NRc No/NR NA
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competence is present.20,23,41
When all 10 studies22,23,26,28,31,33,36,38,41,46 were in-
cluded in meta-analysis, surgery was associated with non-
significant reduction in the risk of varicosity recurrence
compared with liquid sclerotherapy (RR 0.56; 95% CI,
0.29-1.06; I  93%). However, when the three studies
with 2 years follow-up were excluded, the decreased risk
of recurrence with surgery became statistically significant
(RR, 0.45; 95%CI, 0.22-0.93; I2 93%).Moreover, when
older studies (1980) were excluded in sensitivity analy-
sis,26,31,33,41 the results remained statistically significant
(RR, 0.38; 95% CI, 0.16-0.90; I2  94%). No significant
associations were found with other outcomes such as the
risk of PE in four studies (RR 0.30; 95% CI, 0.06-1.46;
I2  0%) and the proportion of patients satisfied (86% vs
82%; P .71); however, the small number of events makes
these estimates imprecise. Data on quality of life and DVT
were sparse and insufficient for meta-analysis.
The included trials had significant methodologic limi-
tations, considering that randomization methods were not
well described, allocation concealment was only conducted
in two studies,33,56 follow-up duration was short in several
studies,26,36,56 and outcome assessors were not blinded in
all studies. In addition, many studies focused on ultrasound
measurements rather on patient-important outcomes.
Considering the overall limitations, indirectness of out-
comes, and imprecision, the quality of evidence in these
studies is low but supports that surgery is associated with a
lower risk of varicosity recurrence.
Sclerotherapy vs conservative management. In
pregnant women with lower leg varicosities, one RCT
showed that liquid sclerotherapy (using the Fegan tech-
nique with injection of sodium tetradecyl in probable sites
of perforator vein incompetence) was superior to conserva-
tive management with compression stockings in cosmetic
results and symptomatic relief. The treatment was rated as
“poor” by 2% of the patients who received sclerotherapy
and by 50% of those who received conservative manage-
ment.27 The quality of this evidence is low due to poor
reporting of bias protection measures.
Sclerotherapy vs laser therapy. We did not find com-
parative studies of endovascular laser ablation of the saphe-
nous veins. We found a small pilot study that used transcu-
taneous long-pulse laser in the treatment of small leg veins
(branch varicosities and spider veins). Results were similar
to sclerotherapy with sodium tetradecyl in esthetic results
and patient satisfaction. The patients in this study were
nonpregnant women with small leg vein varicosities of 0.25
to 3 mm.18 The quality of evidence supporting equivalence
is considered very low due to lack of randomization, impre-
cision (very small sample size), and the short follow-up
duration (3 months).
Liquid sclerotherapy vs foam sclerotherapy. An ob-
servational study by Yamaki et al24 showed that at 1 year,
duplex-guided foam sclerotherapy was superior to duplex-
guided liquid sclerotherapy in achieving complete occlu-
sion of the GSV (67.6% vs 17.5%; P  .0001) and varicose oein recurrence (8.1% vs 25%; P  .048). However, the
nference from this study that supports the superiority of
oam is weakened by the small sample size (77 limbs), the
hort duration of follow-up, and the observational nature
f the study; all these factors make the assessment of the
utcome of varicose recurrence less valid.
aser and radiofrequency studies
Endovenous laser ablation vs surgery. We found
our RCTs that compared endovenous laser ablation with
tandard ligation and stripping. No difference was detected
etween the two procedures at 3 months in improvements
n quality of life scores (Short Form-36),48 disease-specific
uality of life (Aberdeen Varicose Vein Symptom Score
AVVSS]),34 and symptoms (Venous Clinical Severity
core [VCSS]).48 There was slightly increased postopera-
ive pain and bruising in the high ligation and stripping
roup.48 In studies with relatively longer follow-up, no
ifference was detected at 26 months between the two
rocedures in esthetic results, patient satisfaction, and
ain.35,57 Compared with surgery, the laser group had
aster return to normal activity (median, 2 vs 7 days),34
eturn to work (median, 4 vs 17 days),34 and shorter
uration of postoperative disability (total days of sick leave,
.6 vs 22.4 days).54 DVT and PE outcomes were mostly
ot reported.
In general, these trials had short follow-up, whichmade
t difficult to assess varicose vein recurrence; hence, a meta-
nalysis was not feasible. Two of the four trials reported
or-profit funding,34,48 and none reported allocation con-
ealment or blinded outcome assessment. The overall qual-
ty of evidence supporting equivalence is considered very
ow in this comparison.
Radiofrequency vs surgery. Four RCTs and three
bservational studies compared radiofrequency endolumi-
al ablation with surgery in patients with symptomatic
aricose veins.17,19,21,40,43,47,51,58,59 These studies had
hort-term follow-up, with the longest study extending to
years. Endovascular obliteration of the GSV compared
ith conventional vein stripping was associated with faster
eturn to work (1.15 vs 3.89 days; P .02), shorter time to
eturn to normal activity (7 vs 14 days; P  .05),51 lower
ain scores,58 better short-term quality of life scores,58 and
igher patient satisfaction.51 A meta-analysis of these stud-
es shows no significant difference between the two proce-
ures on varicosity recurrence (RR, 0.94; 95% CI, 0.25-
.46; I2  50%; 4 studies).
The RCTs in this comparison did not report bias pro-
ection measures, whereas the observational studies had
omparable groups in age, sex, and clinical CEAP class;
herefore, the evidence of this comparison is of low quality.
Laser saphenous ablation vs radiofrequency abla-
ion. Morrison reported results in 50 patients with varicos-
ty and bilateral GSV reflux whose legs were randomized to
aphenous vein ablation using laser energy or radiofre-
uency energy. At 1 year, they reported complete occlusion
f GSV in 66% of the laser-treated legs compared with 80%
f the radiofrequency-treated legs (P  .05). DVT inci-
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was 1% in both groups.45
Ravi et al25 compared laser and radiofrequency en-
dovenous ablation of GSV and SSV in a nonrandomized
retrospective study and were unable to detect a difference
between the two procedures in effectiveness and safety. The
rate of saphenous vein occlusion 2 weeks after the proce-
dure was about 96% in both groups. Ultrasound examina-
tion of the saphenofemoral junction demonstrated a lack of
neovascularity and the presence of a patent saphenofemoral
junction with physiologic drainage in all patients. Follow-up
at a mean of 3 years showed no neovascularization in the
groin and marked symptomatic improvement in most pa-
tients in both groups. Most of the patients in this series
required additional procedures, however, such as micro-
phlebectomy or sclerotherapy at the time of endovascular
ablation, making these results less reliable. There were no
DVTs in either group. Conclusions regarding the superior-
ity of one of these two interventions were quite limited.
Endovenous laser ablation vs conservative manage-
ment for venous ulcers. Viarengo et al53 randomized 52
patients presenting with varicose veins with active ulcers for
1 year to endovenous laser ablation of GSV and SSV or to
elastic and inelastic compression therapy. The laser group
had higher healing rate at 3 months (63% vs 12%; P 
.0002) and 12 months (82% vs 24%; P  .0001). No
patient in either group experienced a DVT or PE. They
reported complete occlusion, with no treatment failures or
recanalization in all patients treated with laser ablation.
Transient paresthesia occurred in 22% but completely re-
solved after 6 months. Minor adverse effects were reported
such as hyperpigmentation (4%), ecchymoses (63%),
periprocedural pain (33%), lipoid necrosis (4%), and scar-
ring (4%).
Methodologic limitations (randomization, allocation
concealment, and blinding procedures were not reported)
and imprecision (small number of events despite statistical
significance) lower the quality of evidence supporting the
superiority of laser treatment.
Surgery studies
Surgery vs conservative management. Five RCTs
compared various surgical techniques vs conservative man-
agement with compression stockings. Michaels et al44 ran-
domized patients with uncomplicated primary varicose
veins of the lower extremities to flush ligation of the saphe-
nous vein and GSV stripping or to conservative manage-
ment. After 2 years of follow-up, surgical patients reported
better quality of life in quality-adjusted life years (QALYs)
based on the SF-6D score (0.083; 95% CI, 0.005-0.16)
and on the EQ-5D score (0.13; 95% CI, 0.016-0.25).
Significant benefits were also seen in symptomatic and
anatomic measures.44
van Gent et al52 compared ambulatory compression
therapy with subfacial endoscopic perforating vein surgery
vs conservative management in patients with active venous
leg ulcers. They could not detect a significant difference
between the two groups in healing rates (83% in the surgi- sal group and 73% in the conservative group; P  .05) or
ecurrence rates (22% surgical vs 23% conservative; P 
05); however, patients with recurrent ulceration or with
edially located ulcers treated surgically had higher ulcer-
ree rates of 62% vs 33% (P .02) and 78% vs 43% (P .02,
espectively).52 Gohel et al39 (Comparison of Surgery and
ompression with Compression Alone in Chronic Venous
lceration [ESCHAR] trial) monitored patients with open
r recently healed leg ulcers and superficial venous reflux
ho were randomized to surgery with compression therapy
s compression therapy. Surgical correction of superficial
enous reflux in addition to compression bandaging did
ot significantly improve ulcer healing at 4 years (93% for
urgery vs 89% for the conservative management; P  .73)
ut reduced the recurrence of ulcers (31% for surgery vs
6% for the conservative management; P  .01) and re-
ulted in a greater proportion of ulcer-free time at 3 years
78% vs 71%; P  .007).
However, because compression abolishes saphenous
eflux in a nonsurgical way, it should not be surprising that
urgery in addition to compression did not shorten healing
imes. If surgery only, without compression, had been
ncluded in the trial, it would be plausible that the healing
ime would have been similar to that shown in observa-
ional studies.53,60 In an era when surgery has become an
utpatient procedure, it is unclear whether lengthy com-
ression is needed; particularly, because the effect of com-
ression on cost or quality of life outcomes is not well
ocumented.
Two studies only reported laboratory and physiologic
easurements and did not report the clinical outcomes of
nterest. In the first study, patients with chronic venous
nsufficiency and healed venous ulcers were randomized to
urgery (ligation of incompetent lower leg communicating
eins, ablation of incompetent superficial veins, and below
nee graduated compression elastic stocking) or to a con-
rol group that only received compression therapy. Calf
unction measurements did not improve by surgery.50 In
he second study, selective saphenous vein repair with
lication for patients with superficial venous incompetence
ncreased refilling time and decreased incompetent sites
ompared with conservative management with stockings.29
Two of the RCTs protected randomization by conceal-
ng allocation and their rates of loss to follow-up were
mall,39,52 but none of them blinded outcome assessors.
ence, the overall quality of evidence in this comparison
upporting surgery is moderate.
Surgery vs foam therapy. In a noninferiority, 1-year
CT, Wright, et al55 compared the efficacy of a microfoam
reparation injected under ultrasound guidance in patients
ith varicose veins and/or SSV incompetence vs sclero-
herapy or surgery, consisting of high ligation (91.5%);
tripping (88.3%), and avulsion phlebectomy (53.2%).
hen the end point of ultrasound-determined occlusion of
runk vein and resolution of reflux was considered, foam
herapy was noninferior to the comparator therapies and
as associated with less pain and faster return to work. The
tudy had a short follow-up time of 1 year.
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ligation and GSV stripping and phlebectomies, or to SFJ
ligation under local anesthetics and foam sclerotherapy to
the GSV. At 3 months, both groups had similar reduction
in the median CEAP class from preoperative value of C4 to
a value of C1. Sclerotherapy however, was associated with
faster return to normal activities (2 vs 8 days), better
reduction of VCSS (sclerotherapy group median VCSS
dropped from 5 to 1 and surgery median dropped from 7 to
3; P  .001), and reduced overall cost by almost 50%.32
Allocation was concealed in both of these RCTs; how-
ever, the short duration of follow-up renders the assess-
ment of outcomes of interest less valid and the quality of
evidence is low. These studies were sponsored by commer-
cial funding sources (foam manufacturers). The quality of
evidence supporting equivalence is considered low.
Other surgical studies. Jakobsen42 compared radical
surgery, including saphenofemoral and/or saphenopopli-
teal ligation, GSV and/or SSV stripping, ligation of incom-
petent perforating veins located by clinical examination,
and avulsion of tributaries, with minimally-invasive surgery
(ligation under local anesthesia) and sclerotherapy. At 3
years, radical surgery was associated with better esthetic and
symptomatic results.
Rutgers et al49 compared stripping and local avulsions
of varicose veins vs high ligation of the saphenofemoral
junction and sclerotherapy. Cosmetic results, judged by
both the patient and the surgeon, and clinical and Doppler
ultrasound results, were significantly better after the strip-
ping operation.
Dwerryhouse et al37,61 compared flush ligation of the
saphenofemoral junction with subsequent diathermy avul-
sion of all the visible varicose tributaries vs a combination of
ligation and GSV stripping to the knee. After 5 years of
follow-up, they found that stripping had significantly de-
creased the need for reoperation (RR, 0.28; 95% CI,
Table II. Commonly reported adverse events
Surgery Sclerotherapy Laser
● Wound infection,
3%-6%
● Skin staining or
necrosis, 3%
● Purpura/b
11%-23%
● Sural or saphenous
nerve injury, 10%-
23%
● Superficial phlebitis,
22%-27%
● Erythema
● Hematoma, 31% ● Hyperpigm
57%
● Superficial phlebitis,
0%-12%
● Hypopigm
● Blistering/
7%
● Scaring, 1
● Telangiec
28%
● Edema, 1
● Paresthesi
● Superficia0.13-0.59). (When surgery is compared with all endoluminal abla-
ion therapies (laser, radiofrequency, and foam), meta-
nalysis shows that surgery led to a nonsignificant reduction
n the risk of varicose vein recurrence (RR, 0.63; 95% CI,
.37-1.07; I 2  90%; 16 studies).
dverse effects
In general, all treatments for varicose veins were well
olerated, without significant periprocedural adverse ef-
ects; particularly, DVT and PE in these studies were very
nfrequently reported. Local complications were common
ut were generally minor. Table II summarizes the re-
orted frequency of local complications associated with
urgery, liquid sclerotherapy, laser ablation, radiofrequency
blation, and foam therapy. Laser and radiofrequency ab-
ation studies reported more side effects than sclerotherapy
nd surgery studies, which could be attributed to differen-
ial reporting of minor side effects.
ISCUSSION
Our findings. In the systematic review, we searched
he literature for studies that compared different treatment
odalities for varicose veins. We found 38 studies that met
ligibility criteria and compared different permutations of
he available approaches to treating varicose veins and the
ncompetent saphenous veins. In general, invasive treat-
ents (surgical and endoluminal) were superior to conser-
ative management in elimination of varicose veins and
ecreasing ulcer recurrence rates. Studies of liquid sclero-
herapy, foam, and endoluminal thermal ablation therapies
ad short follow-up time, making them unsuitable to assess
ong-term outcomes.
Surgery appears to have low- to moderate-quality evi-
ence demonstrating less recurrence and better long-term
esults. Compared with surgery, however, liquid or foam
clerotherapy and endoluminal thermal ablation therapies
on Radiofrequency ablation Foam therapy
ng, ● Saphenous nerve
paresthesia, 13%
● Contusion,
bruising,
hematoma, 61%
● Superficial phlebitis,
0%-20%
● Skin pigmentation,
51%
tion, ● Hematoma, 7% ● Headache, 11%
tion, 2% ● Thermal skin injury, 7%
ghing, ● Paresthesia, 1%
● Leg edema, 1%
atting,
-2%
bitis, 6%ablati
ruisi
, 33%
enta
enta
slou
3%
tatic m
5%
a, 1%laser and radiofrequency) were associated with faster re-
b
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The evidence on quality of life was sparse and inconclusive.
Data on outcomes of DVT and PE were sparse and poorly
reported. There were insufficient data to conduct many
planned meta-analyses and subgroup analyses, particularly
analysis based on CEAP class.
The quality of evidence in this review is low to very low.
Although the evidence is mainly derived from randomized
trials, it was downgraded12 because the subjective out-
comes in these studies were not assessed by blinded asses-
sors, the number of events was low, which led to impreci-
sion (ie, wide CIs, high P values for comparisons in which
large differences could not be excluded), and there was
great inconsistency in patients, interventions, and results
across studies. Furthermore, many studies designated sur-
rogate markers as end points, such as refilling time and
other ultrasonographic measures, that indirectly apply to
the outcomes of interest, further weaken clinical inferences,
and therefore lower the overall quality of evidence.
The strengths of our review stem from the comprehen-
sive literature search strategy that had no language restric-
tions and included randomized and observational, compar-
ative (controlled) studies. We also attempted to reduce bias
by reviewing articles, extracting data, and appraising the
literature by pairs of blinded reviewers with adequate inter-
observer agreement.
Comparison with other reviews. Van de Bos et al62
compared the different treatments available for varicosities
and concluded that they all had a high success rate (70%),
with better results with endovenous laser therapy. These
conclusions were based only on ultrasonographic out-
comes, and many of the included studies were noncom-
parative; hence, the quality of evidence presented in that
review was affected by the indirectness of outcomes and the
methodologic limitations of the primary evidence. Rigby et
al63 qualitatively summarized RCTs that compared sclero-
therapy and surgery and did not offer a meta-analytic
estimate. They concluded that sclerotherapy is associated
with a favorable recurrence rate in the first year but that
surgery has better long-term outcomes, a finding consistent
with our review.
Bamigboye et al64 summarized varicose veins treat-
ments in pregnancy and only found one RCT that demon-
strated modest beneficial effects of a phlebotonic drug
(rutoside) in reducing symptoms of varicose veins (noctur-
nal cramps, feelings of tiredness, paresthesia). Jia et al8
summarized studies of foam therapy, including noncom-
parative studies, and concluded that serious side effects
were rare (DVT and PE1%; visual disturbances, headache
and thrombophlebitis5%); however, data were inconclu-
sive regarding effectiveness.
Similarly, Mundy et al6 summarized studies of laser
therapy, including noncomparative studies, and concluded
that serious periprocedural adverse effects such as DVT and
incorrect placement of the laser in blood vessels were
uncommon. They were also unable to draw inferences
regarding effectiveness and varicose veins recurrence rates tecause of the paucity of comparative studies with long-
erm follow-up.
Luebke and Brunkwall65 summarized studies of endo-
uminal thermal ablation and foam therapy, including non-
omparative studies, and concluded that all three were fairly
afe with good short-term and midterm results.
Implications for practice and research. The clinical
nd practical implications of this review are explained in the
ccompanying clinical practice guidelines from the venous
ommittee from the SVS and the AVF. In terms of impli-
ations for future research, there is apparent need for ran-
omized trials of newer and less invasive therapies, such as
aser, radiofrequency ablation, and foam therapy, to com-
are their efficacy and safety with that of the standard
rocedure of ligation, stripping, and multiple phlebecto-
ies. These studies need to stratify participants by the
everity of symptoms, such as by the VCSS, and/or other
easures of disease severity, including physical examination
r imaging findings. This is particularly important because
dvanced stages of chronic venous insufficiency (CEAP C4,
5, and C6) may be associated with limitations or contra-
ndications to surgical treatment by conventional vein strip-
ing, including extensive dermatosclerosis, fibrosis, ulcer
carring sequelae, active ulcers, edema, or lymphedema,
hus making the use of alternative methods of treatment
ecessary.53
In addition, future studies should have a long follow-up
uration (possibly 5 years or longer), assess patient-important
utcomes, such as varicose vein recurrence, patient satisfac-
ion, disability, and quality of life; and use standardized
isease-specific scales for these outcomes, such as the VCSS
nd the Venous Disability Score.
The expertise-based RCT is likely the optimal design
or future studies: in traditional RCTs, patients are random-
zed to treatment A or treatment B, administered by the
ame clinician, whereas in expertise-based RCTs, patients
re randomized to clinician A or clinician B, and each
linician administers the procedure in which they have the
est expertise.66 Indeed, we found examples in this review
f studies in which treatment groups were imbalanced in
ize, suggesting expertise or preference biased toward a
articular treatment.20
Lastly, there is general paucity of data on the cost-
ffectiveness of these procedures.2,63 This is another area
hat requires careful assessment considering that proce-
ures are done for a wide range of indications that include
osmesis.
ONCLUSION
Very low quality evidence suggests that the available
reatments for varicose veins (surgery, sclerotherapy, foam
herapy, laser endoluminal ablation and radiofrequency
ndoluminal ablation) appear to be safe with rare side
ffects. Surgery is the only treatment with long-term effec-
iveness data. The other less invasive treatments are associ-
ted with shorter disability and less pain, but only short-
erm effectiveness data.
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